Joseph Hsin-I Chou, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Growth Charts | 1 | 2020 | 60 | 0.650 |
Why?
|
| Smell | 3 | 2001 | 259 | 0.270 |
Why?
|
| Helminth Proteins | 3 | 2001 | 173 | 0.230 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2024 | 30 | 0.220 |
Why?
|
| Jaundice, Neonatal | 1 | 2024 | 70 | 0.220 |
Why?
|
| Genes, Helminth | 3 | 2001 | 146 | 0.210 |
Why?
|
| Hypothermia | 1 | 2024 | 190 | 0.200 |
Why?
|
| Telemedicine | 1 | 2020 | 3108 | 0.200 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2023 | 109 | 0.190 |
Why?
|
| Social Work | 1 | 2023 | 158 | 0.190 |
Why?
|
| Infant, Premature | 3 | 2024 | 2121 | 0.180 |
Why?
|
| Caenorhabditis elegans | 5 | 2001 | 1480 | 0.160 |
Why?
|
| Substance Abuse Detection | 1 | 2022 | 301 | 0.160 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 858 | 0.140 |
Why?
|
| Cannabis | 1 | 2023 | 446 | 0.130 |
Why?
|
| Caenorhabditis elegans Proteins | 2 | 2001 | 887 | 0.130 |
Why?
|
| Infant, Newborn | 9 | 2024 | 26380 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2023 | 1098 | 0.130 |
Why?
|
| Informed Consent | 1 | 2022 | 1010 | 0.120 |
Why?
|
| Delivery, Obstetric | 1 | 2022 | 947 | 0.120 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 587 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2020 | 896 | 0.100 |
Why?
|
| Indomethacin | 1 | 2013 | 322 | 0.100 |
Why?
|
| Receptors, Odorant | 3 | 1997 | 67 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 3 | 1993 | 832 | 0.090 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 1993 | 1137 | 0.090 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1993 | 403 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 2 | 2024 | 712 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2024 | 3847 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 2177 | 0.070 |
Why?
|
| Infant | 5 | 2023 | 36426 | 0.070 |
Why?
|
| Premature Birth | 1 | 2020 | 1830 | 0.070 |
Why?
|
| Diacetyl | 2 | 1997 | 21 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 4418 | 0.070 |
Why?
|
| Escherichia coli | 3 | 1993 | 4210 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2024 | 81537 | 0.060 |
Why?
|
| Babesiosis | 1 | 2006 | 92 | 0.060 |
Why?
|
| Medicare | 1 | 2023 | 6815 | 0.060 |
Why?
|
| Delivery Rooms | 1 | 2024 | 39 | 0.060 |
Why?
|
| Hyperbilirubinemia | 1 | 2024 | 74 | 0.060 |
Why?
|
| Research Design | 1 | 2020 | 6204 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2001 | 7847 | 0.060 |
Why?
|
| Body Temperature Regulation | 1 | 2024 | 291 | 0.050 |
Why?
|
| Olfactory Receptor Neurons | 2 | 2001 | 95 | 0.050 |
Why?
|
| Chemotaxis | 3 | 2001 | 596 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 439 | 0.050 |
Why?
|
| Consent Forms | 1 | 2022 | 55 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2023 | 138 | 0.050 |
Why?
|
| Pentanones | 1 | 2001 | 12 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 2649 | 0.050 |
Why?
|
| DNA, Helminth | 1 | 2001 | 36 | 0.050 |
Why?
|
| RNA, Helminth | 1 | 2001 | 60 | 0.040 |
Why?
|
| Phototherapy | 1 | 2024 | 369 | 0.040 |
Why?
|
| Pregnancy | 4 | 2023 | 30230 | 0.040 |
Why?
|
| Genes, Bacterial | 3 | 1993 | 1076 | 0.040 |
Why?
|
| Multigene Family | 2 | 2001 | 1081 | 0.040 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 1991 | 209 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 42510 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 2743 | 0.040 |
Why?
|
| Superoxide Dismutase | 2 | 1991 | 593 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12529 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 2824 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1716 | 0.030 |
Why?
|
| Female | 9 | 2024 | 396141 | 0.030 |
Why?
|
| Chemoreceptor Cells | 1 | 1995 | 87 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2001 | 1103 | 0.030 |
Why?
|
| Gestational Age | 1 | 2024 | 3616 | 0.030 |
Why?
|
| Humans | 13 | 2024 | 765926 | 0.030 |
Why?
|
| Placenta | 1 | 2023 | 1726 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 13398 | 0.030 |
Why?
|
| Neurons, Afferent | 1 | 1996 | 496 | 0.030 |
Why?
|
| Child | 4 | 2024 | 80568 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 1993 | 135 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2001 | 17596 | 0.030 |
Why?
|
| Base Sequence | 2 | 2001 | 12405 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2020 | 1363 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 1993 | 393 | 0.020 |
Why?
|
| DNA Transposable Elements | 2 | 1991 | 765 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2022 | 9656 | 0.020 |
Why?
|
| Operon | 1 | 1990 | 371 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3886 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1990 | 373 | 0.020 |
Why?
|
| Endodeoxyribonucleases | 1 | 1990 | 165 | 0.020 |
Why?
|
| Superoxides | 1 | 1990 | 382 | 0.020 |
Why?
|
| Male | 6 | 2024 | 363815 | 0.020 |
Why?
|
| Massachusetts | 1 | 2022 | 8882 | 0.020 |
Why?
|
| Zidovudine | 1 | 1989 | 626 | 0.020 |
Why?
|
| Mutagenesis | 1 | 1991 | 1226 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 3834 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1993 | 2219 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1995 | 2814 | 0.020 |
Why?
|
| Babesia | 1 | 2006 | 29 | 0.020 |
Why?
|
| Incidence | 1 | 2024 | 21513 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2001 | 12768 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1989 | 567 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 1990 | 1056 | 0.010 |
Why?
|
| Animals | 6 | 2006 | 168735 | 0.010 |
Why?
|
| Antioxidants | 1 | 1990 | 1671 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 14643 | 0.010 |
Why?
|
| United States | 2 | 2023 | 72909 | 0.010 |
Why?
|
| Adult | 3 | 2023 | 223088 | 0.010 |
Why?
|
| Cell Survival | 1 | 1989 | 5745 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1989 | 2916 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12822 | 0.010 |
Why?
|
| Mutation | 2 | 2001 | 30192 | 0.010 |
Why?
|
| Transduction, Genetic | 2 | 1991 | 898 | 0.010 |
Why?
|
| Citric Acid | 1 | 1997 | 124 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1989 | 3405 | 0.010 |
Why?
|
| Pyruvic Acid | 1 | 1997 | 205 | 0.010 |
Why?
|
| 1-Octanol | 1 | 1995 | 7 | 0.010 |
Why?
|
| Octanols | 1 | 1995 | 25 | 0.010 |
Why?
|
| Benzaldehydes | 1 | 1995 | 59 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15828 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 20133 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1997 | 6491 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 944 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 3049 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29890 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1995 | 1524 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1995 | 2270 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 24275 | 0.010 |
Why?
|
| Deoxyribonuclease IV (Phage T4-Induced) | 1 | 1990 | 8 | 0.010 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1990 | 18 | 0.010 |
Why?
|
| R Factors | 1 | 1990 | 35 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 1995 | 1563 | 0.010 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 1990 | 71 | 0.010 |
Why?
|
| Pyrazines | 1 | 1996 | 1204 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1991 | 752 | 0.010 |
Why?
|
| Aged | 1 | 2023 | 171163 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1997 | 3945 | 0.010 |
Why?
|
| Transfection | 1 | 1997 | 5738 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1989 | 351 | 0.010 |
Why?
|
| Erythroblasts | 1 | 1989 | 142 | 0.000 |
Why?
|
| Vitamin K | 1 | 1991 | 312 | 0.000 |
Why?
|
| Behavior, Animal | 1 | 1995 | 1866 | 0.000 |
Why?
|
| Granulocytes | 1 | 1989 | 548 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3733 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2013 | 65194 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 1384 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 10727 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1989 | 1751 | 0.000 |
Why?
|
| Transcriptional Activation | 1 | 1991 | 1743 | 0.000 |
Why?
|
| Sex Characteristics | 1 | 1995 | 2645 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 4163 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 4780 | 0.000 |
Why?
|
| Calcium | 1 | 1997 | 5769 | 0.000 |
Why?
|
| Signal Transduction | 2 | 1997 | 23597 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1989 | 2075 | 0.000 |
Why?
|
| Gene Expression | 1 | 1995 | 7581 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 2 | 1991 | 7473 | 0.000 |
Why?
|
| Cell Division | 1 | 1989 | 4466 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1997 | 18962 | 0.000 |
Why?
|
| Virus Replication | 1 | 1989 | 2450 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1996 | 11895 | 0.000 |
Why?
|
| Genotype | 1 | 1991 | 13026 | 0.000 |
Why?
|
| Macrophages | 1 | 1989 | 5772 | 0.000 |
Why?
|
| Phenotype | 1 | 1991 | 16714 | 0.000 |
Why?
|
| HIV-1 | 1 | 1989 | 6945 | 0.000 |
Why?
|